TAVR术后传导障碍的临床影响:系统评价与荟萃分析
该系统评价与荟萃分析纳入30项研究,评估TAVR术后新发持续性左束支传导阻滞(NOP-LBBB)和永久起搏器植入(PPI)对1年临床结局的影响。结果显示NOP-LBBB与全因死亡、心源性死亡、心衰住院及1年内需PPI风险升高相关;围术期PPI与全因死亡和心衰住院风险升高相关,但与心源性死亡无关。
要点
- TAVR术后NOP-LBBB增加1年全因死亡、心源性死亡、心衰住院及需PPI的风险。
- TAVR围术期PPI增加1年全因死亡和心衰住院风险,但不增加心源性死亡风险。
- 需加强TAVR术后传导障碍的预防与优化管理。
核心结论
- TAVR术后NOP-LBBB和PPI均与1年全因死亡和心衰住院风险升高相关。
- 围术期NOP-LBBB还增加心源性死亡及术后1年内需PPI的风险。
研究设计与样本
- 系统检索PubMed和EMBASE数据库,纳入报告TAVR术后NOP-LBBB或围术期PPI的1年临床影响原始数据的研究。
主要发现
- NOP-LBBB与1年全因死亡风险升高相关(RR 1.32,95%CI 1.17-1.49;P<0.001)。
- NOP-LBBB与1年心源性死亡风险升高相关(RR 1.46,95%CI 1.20-1.78;P<0.001)。
- NOP-LBBB与1年心衰住院风险升高相关(RR 1.35,95%CI 1.05-1.72;P=0.02)。
- NOP-LBBB与1年需PPI风险升高相关(RR 1.89,95%CI 1.58-2.27;P<0.001)。
- 围术期PPI与1年全因死亡风险升高相关(RR 1.17,95%CI 1.11-1.25;P<0.001)及心衰住院风险升高相关(RR 1.18,95%CI 1.03-1.36;P=0.02),与心源性死亡无关(RR 0.84,95%CI 0.67-1.05;P=0.13)。
临床怎么用
- TAVR术后应关注新发持续性左束支传导阻滞,因其与不良结局及后续起搏器需求相关。
- 围术期永久起搏器植入者也需加强随访,警惕全因死亡和心衰住院风险。
局限性
- 需进一步研究以加强预防措施并优化TAVR术后传导障碍的管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The clinical impact of new-onset persistent left bundle branch block (NOP-LBBB) and permanent pacemaker implantation (PPI) on transcatheter aortic valve replacement (TAVR) recipients remains controversial. We aimed to evaluate the impact of (i) periprocedural NOP-LBBB and PPI post-TAVR on 1-year all-cause death, cardiac death, and heart failure hospitalization and (ii) NOP-LBBB on the need for PPI at 1-year follow-up. METHODS AND RESULTS: We performed a systematic search from PubMed and EMBASE databases for studies reporting raw data on 1-year clinical impact of NOP-LBBB or periprocedural PPI post-TAVR. Data from 30 studies, including 7792 patients (12 studies) and 42 927 patients (21 studies) for the evaluation of the impact of NOP-LBBB and PPI after TAVR were sourced, respectively. NOP-LBBB was associated with an increased risk of all-cause death [risk ratio (RR) 1.32, 95% confidence interval (CI) 1.17-1.49; P < 0.001], cardiac death (RR 1.46, 95% CI 1.20-1.78; P < 0.001), heart failure hospitalization (RR 1.35, 95% CI 1.05-1.72; P = 0.02), and PPI (RR 1.89, 95% CI 1.58-2.27; P < 0.001) at 1-year follow-up. Periprocedural PPI after TAVR was associated with a higher risk of all-cause death (RR 1.17, 95% CI 1.11-1.25; P < 0.001) and heart failure hospitalization (RR 1.18, 95% CI 1.03-1.36; P = 0.02). Permanent pacemaker implantation was not associated with an increased risk of cardiac death (RR 0.84, 95% CI 0.67-1.05; P = 0.13). CONCLUSION: NOP-LBBB and PPI after TAVR are associated with an increased risk of all-cause death and heart failure hospitalization at 1-year follow-up. Periprocedural NOP-LBBB also increased the risk of cardiac death and PPI within the year following the procedure. Further studies are urgently warranted to enhance preventive measures and optimize the management of conduction disturbances post-TAVR.
引用
- Faroux L, Chen S, Muntané-Carol G, et al. Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis. Eur Heart J. 2020. PMID: 31899484. doi:10.1093/eurheartj/ehz924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。